Advertisement
ALNY vs ARGX
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. argenx (ARGX) Stock Comparison
Key Takeaways
- ALNY has outperformed ARGX year-to-date with a 27% gain compared to ARGX's 5%, driven by strong product sales.
- Both companies operate in the biotech sector targeting rare diseases, but ALNY leverages RNA interference (RNAi, a gene-silencing technology) while ARGX focuses on immunology with antibody therapies.
- Recent quarterly earnings for ALNY beat estimates on Amvuttra uptake, while ARGX prepares for Q1 results amid pipeline advancements.
- Market caps are comparable at $38.6 billion for ALNY and $49.9 billion for ARGX, reflecting similar scale in innovative therapies.
- Low betas indicate relative stability: ALNY at 0.30 and ARGX at -0.06, appealing to growth-oriented investors seeking biotech exposure with moderated volatility.
- Analyst targets suggest upside: $449 for ALNY and $1,036 for ARGX.
Introduction
Alnylam Pharmaceuticals (ALNY) and argenx (ARGX) represent leading biotech firms specializing in treatments for rare diseases, drawing interest from growth-focused traders and long-term investors. Both stocks have navigated volatile market conditions in recent months, influenced by clinical data, earnings, and sector sentiment. This comparison examines their business models, recent performance, and relative positioning to aid decisions in the competitive biotech landscape. With innovative pipelines and strong revenue growth, these stocks offer insights into sector trends like gene therapies and immunology, relevant for portfolios seeking high-upside opportunities amid broader market rotations.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) develops RNAi therapeutics for genetically defined diseases, with key products like Amvuttra for transthyretin amyloidosis (ATTR). In recent market activity, the stock has traded around $289, down from a 52-week high of $496 but up 27% year-to-date, reflecting resilience amid biotech swings. First-quarter 2026 earnings exceeded expectations, propelled by Amvuttra sales growth and durable demand despite competition, boosting sentiment. Broader factors include pipeline progress in ATTR-CM (cardiac amyloidosis) and collaborations like with Viz.ai. Trading volume remains steady, with a market cap near $38.6 billion and low beta of 0.30 signaling stability. Investor focus centers on sustained revenue expansion and profitability margins reaching 12.6%.
ARGX Overview and Recent Performance
argenx (ARGX), a biopharmaceutical company, targets severe autoimmune diseases using antibody-based therapies, led by Vyvgart for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Shares recently hovered near $798, below the 52-week high of $935 but up 5% year-to-date, with some quarterly slips tied to European ADR trends. Positive developments include new Vyvgart data at the 2026 AAN meeting, highlighting neuromuscular applications and pipeline strength. Upcoming first-quarter results on May 7 underscore growth potential, supported by $4.2 billion in prior full-year sales. Market cap stands at $49.9 billion, with an ultralow beta of -0.06 and profit margins at 30.5%, attracting attention for its immunology focus amid expanding indications.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and market conditions. Only 25 bots earn a spot based on superior metrics amid current volatility, showcasing annualized returns ranging from 26% to 162%, win rates of 51% to 88%, profit factors up to 7.12, and profit-to-drawdown ratios exceeding 17 in some cases. These include high-frequency scalpers on semiconductors, trend-followers in small caps, and volatility plays on leveraged ETFs, with average trade durations from minutes to weeks. Traders can explore these data-driven tools for automated insights tailored to sectors like biotech. Visit Trending AI Robots to review live performance and copy top strategies.
Head-to-Head Comparison
ALNY and ARGX both drive growth through rare disease therapies but differ in mechanisms: ALNY's RNAi platform offers durable gene silencing, contrasting ARGX's immunology via neonatal Fc receptor (FcRn) blockade for antibody clearance. Recent momentum favors ALNY's 27% YTD gains over ARGX's 5%, tied to earnings beats versus pipeline previews. Risk profiles show low betas for both, though ARGX's negative value implies inverse market correlation. Sector exposure centers on biotech catalysts, with ALNY emphasizing ATTR sales durability amid rivals, and ARGX leveraging Vyvgart expansions in MG and CIDP. Market sentiment reflects analyst optimism, but ALNY's higher PE (73 vs. 41) signals premium valuation for proven revenue, while ARGX trades on broader pipeline potential. Trade-offs include ALNY's established products versus ARGX's higher margins.
Tickeron AI Verdict
Tickeron's AI currently leans toward ALNY based on superior trend consistency, recent earnings momentum, and stronger relative YTD positioning in the biotech space. Factors like Amvuttra-driven stability and lower volatility enhance its appeal over ARGX's promising but pre-earnings pipeline catalysts. This probabilistic edge favors ALNY for near-term relative outperformance, though both maintain growth trajectories warranting monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and ARGX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileARGX’s FA Score has 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- ARGX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while ARGX’s TA Score has 5 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 6 bearish.
- ARGX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.02% price change this week, while ARGX (@Biotechnology) price change was +2.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.27%. For the same industry, the average monthly price growth was +4.35%, and the average quarterly price growth was +11.24%.
Reported Earning Dates
ALNY is expected to report earnings on Jul 30, 2026.
ARGX is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Biotechnology (-1.27% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | ARGX | ALNY / ARGX | |
| Capitalization | 39B | 50.6B | 77% |
| EBITDA | 866M | 1.51B | 57% |
| Gain YTD | -26.561 | -3.336 | 796% |
| P/E Ratio | 73.37 | 36.11 | 203% |
| Revenue | 4.29B | 4.66B | 92% |
| Total Cash | 3.01B | 3.93B | 77% |
| Total Debt | 1.27B | 43.2M | 2,947% |
ALNY | ARGX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 58 | 24 | |
SMR RATING 1..100 | 14 | 39 | |
PRICE GROWTH RATING 1..100 | 64 | 54 | |
P/E GROWTH RATING 1..100 | 100 | 40 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARGX's Valuation (82) in the Pharmaceuticals Other industry is in the same range as ALNY (89) in the Biotechnology industry. This means that ARGX’s stock grew similarly to ALNY’s over the last 12 months.
ARGX's Profit vs Risk Rating (24) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALNY (58) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than ALNY’s over the last 12 months.
ALNY's SMR Rating (14) in the Biotechnology industry is in the same range as ARGX (39) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew similarly to ARGX’s over the last 12 months.
ARGX's Price Growth Rating (54) in the Pharmaceuticals Other industry is in the same range as ALNY (64) in the Biotechnology industry. This means that ARGX’s stock grew similarly to ALNY’s over the last 12 months.
ARGX's P/E Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALNY (100) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than ALNY’s over the last 12 months.
| ALNY | ARGX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 48% |
| Stochastic ODDS (%) | 1 day ago 75% | 2 days ago 61% |
| Momentum ODDS (%) | 1 day ago 74% | 2 days ago 73% |
| MACD ODDS (%) | 1 day ago 76% | 2 days ago 54% |
| TrendWeek ODDS (%) | 1 day ago 64% | 2 days ago 68% |
| TrendMonth ODDS (%) | 1 day ago 70% | 2 days ago 65% |
| Advances ODDS (%) | 7 days ago 76% | 9 days ago 71% |
| Declines ODDS (%) | 2 days ago 66% | 5 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 82% | N/A |
| Aroon ODDS (%) | 1 day ago 72% | 2 days ago 71% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RECS | 42.56 | 0.07 | +0.16% |
| Columbia Research Enhanced Core ETF | |||
| SHYM | 22.16 | -0.01 | -0.05% |
| iShares Short Duration HY Muni Act ETF | |||
| YALL | 44.10 | -0.09 | -0.20% |
| God Bless America ETF | |||
| NTSI | 46.33 | -0.24 | -0.51% |
| WisdomTree International Efficnt Cr ETF | |||
| CLOD | 29.86 | -0.38 | -1.26% |
| Themes Cloud Computing ETF | |||
ARGX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.
| Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
|---|---|---|---|---|
| ARGX | 100% | -0.05% | ||
| ARGNF - ARGX | 55% Loosely correlated | N/A | ||
| ALNY - ARGX | 49% Loosely correlated | +2.52% | ||
| AXON - ARGX | 40% Loosely correlated | -0.18% | ||
| GMAB - ARGX | 36% Loosely correlated | +3.44% | ||
| ARRY - ARGX | 36% Loosely correlated | -6.52% | ||
More | ||||